Azitra (AZTR) Income from Continuing Operations (2022 - 2026)
Azitra (AZTR) posted Income from Continuing Operations of 3927240.0 for Q1 2026, down 75.83% on a QoQ basis from 2233504.0 in Q4 2025, and down 27.99% year-over-year from 5453903.56 in Q1 2025.
Azitra (AZTR) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Azitra's Income from Continuing Operations history runs 5 years deep, the most recent figure standing at 3927240.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 27.99% year-over-year to 3927240.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 11814265.0 (down 29.78% YoY) and the FY2025 annual result came in at 10955370.0, down 22.17% from the prior year.
- Income from Continuing Operations was 3927240.0 for Q1 2026 at Azitra, down from 2233504.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 1009491.0 in Q3 2024 and bottomed at 4429528.0 in Q2 2023.
- A 5-year average of 2639109.94 and a median of 2544586.5 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations jumped 48.05% — and 2025, when it slumped 173.85%.
- Azitra's Income from Continuing Operations stood at 2803140.0 in 2022, then climbed by 12.46% to 2453785.0 in 2023, then increased by 2.47% to 2393133.0 in 2024, then rose by 6.67% to 2233504.0 in 2025, then tumbled by 75.83% to 3927240.0 in 2026.
- Business Quant data shows AZTR's Income from Continuing Operations at 3927240.0 in Q1 2026, 2233504.0 in Q4 2025, and 2764528.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Nanobiotix | 1,785.82 Bn | 1,785.76 Bn | - | - |
| 2 | Akari Therapeutics | 979.03 Bn | 979.03 Bn | - | -14.46 Mn |
| 3 | BeOne Medicines | 472.98 Bn | 468.19 Bn | 1.35 Bn | 227.36 Mn |
| 4 | Vertex Pharmaceuticals | 123.73 Bn | 116.48 Bn | 2.59 Bn | 1.03 Bn |
| 5 | Regeneron Pharmaceuticals | 71.59 Bn | 62.84 Bn | 3.31 Bn | 727.20 Mn |
| 6 | Belite Bio | 62.00 Bn | 62.00 Bn | - | -26.94 Mn |
| 7 | Argenx Se | 54.67 Bn | 49.49 Bn | 1.41 Bn | 482.00 Mn |
| 8 | Alnylam Pharmaceuticals | 37.96 Bn | 34.95 Bn | 959.66 Mn | 205.99 Mn |
| 9 | Revolution Medicines | 36.08 Bn | 36.08 Bn | - | -453.82 Mn |
| 10 | Azitra | 2.07 Mn | 2.07 Mn | - | -3.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.93 Mn |
| Dec 31, 2025 | -2.23 Mn |
| Sep 30, 2025 | -2.76 Mn |
| Jun 30, 2025 | -2.89 Mn |
| Mar 31, 2025 | -3.07 Mn |
| Dec 31, 2024 | -2.39 Mn |
| Sep 30, 2024 | -1.01 Mn |
| Jun 30, 2024 | -2.63 Mn |
| Mar 31, 2024 | -2.93 Mn |
| Dec 31, 2023 | -2.45 Mn |
| Sep 30, 2023 | -1.94 Mn |
| Jun 30, 2023 | -4.43 Mn |
| Mar 31, 2023 | -2.46 Mn |
| Dec 31, 2022 | -2.80 Mn |
| Sep 30, 2022 | -2.40 Mn |
| Jun 30, 2022 | -1.89 Mn |